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Transglutaminase type 2 (TG2) is both a protein cross-linking
enzyme and a cell adhesionmolecule with an elusive unconven-
tional secretion pathway. In normal conditions, TG2-mediated
modification of the extracellularmatrixmodulates cell motility,
proliferation and tissue repair, but under continuous cell insult,
higher expression and elevated extracellular trafficking of TG2
contribute to the pathogenesis of tissue scarring. In search of
TG2 ligands that could contribute to its regulation, we charac-
terized the affinity of TG2 for heparan sulfate (HS) and heparin,
an analogue of the chains of HS proteoglycans (HSPGs). By
using heparin/HS solid-binding assays and surface plasmon res-
onance we showed that purified TG2 has high affinity for hepa-
rin/HS, comparable to that for fibronectin, and that cell-surface
TG2 interacts with heparin/HS.We demonstrated that cell-sur-
face TG2 directly associates with the HS chains of syndecan-4
without themediation of fibronectin, which has affinity for both
syndecan-4 and TG2. Functional inhibition of the cell-surface
HS chains of wild-type and syndecan-4-null fibroblasts revealed
that the extracellular cross-linking activity of TG2 depends on
the HS of HSPG and that syndecan-4 plays a major but not
exclusive role.We found that heparin binding did not alter TG2
activity per se. Conversely, fibroblasts deprived of syndecan-4
were unable to effectively externalize TG2, resulting in its cyto-
solic accumulation. We propose that the membrane trafficking
of TG2, and hence its extracellular activity, is linked to TG2
binding to cell-surface HSPG.
Transglutaminase type 2 (TG2,2 EC 2.3.2.13) is the most
widespread member of a large family of enzymes that catalyze
the Ca2-dependent post-translational modification of pro-
teins leading to intra- or intermolecular N(-glutamyl)lysine
bonds (1, 2). Unlike other family members, TG2 is uniquely
exported through a yet to be elucidated non-conventional path-
way. Once secreted, TG2 finds in the extracellular compart-
ment the ideal conditions of high Ca2 and low GTP concen-
tration for the activation of its intrinsic transamidation activity
(cross-linking) (2, 3). Intracellularly, GTP binding suppresses
the Ca2-dependent cross-linking activity and determines the
additional GTPase activity of TG2 (4, 5), which is responsible
for signal transduction (6). Once externalized, TG2 remains
tightly bound to the cell surface and to the extracellular matrix
(ECM) (7, 8), and it is rarely found free in the conditioned
medium, unless overexpressed by cell transfection (9).
Extracellular TG2activity is involved in the cross-linking of the
ECM, conferring resistance to matrix metalloproteinase and pro-
moting cell-matrix interactions via cross-linking of fibronectin
(FN) and collagen (1, 7, 11, 12). TG2 has an additional non-enzy-
matic role in the matrix as an integrin-1 co-receptor (8) by sup-
porting RGD-independent cell adhesion to FN (8, 13, 14).
Extracellular cross-linking and TG2-mediated adhesion
facilitate the repair process in many tissue compartments (1, 2,
15, 16). On the other hand, uncontrolled cross-linking as a con-
sequence of chronic cell insult and secretion of TG2 has been
implicated in a number of pathological conditions, including
kidney, liver, and pulmonary fibrosis (17–20).
Understanding how TG2 is exported and targeted to the cell
surface is critical for limiting its cellular secretion and extracel-
lular action. Although a key trigger for TG2 export is cell stress
(2, 21, 22), TG2 is not unspecifically released, because extracel-
lular trafficking occurs in the absence of leakage of intracellular
components and cells remain viable (23). We know that TG2
requires the tertiary structure of its active site region to be
secreted (9); moreover, TG2 is acetylated on the N terminus
(24), a process reported to affect membrane targeting of non-
conventional secreted proteins (25). Two main binding part-
ners for TG2, FN and integrin-1, have both been attributed a
possible role in the transport of TG2 to the cell surface (8, 26).
FN was shown to co-localize with TG2 once released (26), and
integrin-1 to co-associate with TG2 in cells induced to differ-
entiate (8).
TG2 has also long been known to have some affinity for hep-
arin (27, 28), a highly sulfated analogue of heparan sulfate (HS)
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glycosaminoglycan chains, which are abundant constituents of
the cell surface/ECM. HS chains are linear polysaccharides
consisting of alternating N-acetylated or N-sulfated glucosa-
mine units (GlcNAc or GlcNS), and uronic acids (glucuronic
acid GlcA or iduronic acid IdoA residues) (29), which only exist
covalently bound to the core protein of cell-surface proteogly-
cans (syndecans and glypicans) and secreted proteoglycans
(29). Heparin binding is a property common to many ECM
proteins (29), but the level of affinity has never been established
for TG2, which makes it difficult to estimate the real biological
significance of this interaction. Heparan sulfate proteoglycans
(HSPG) bind ECM ligands through the HS chains, influencing
their biological activity, trafficking, and secretion. Among the
HSPG subfamilies, the syndecans act as co-receptors for both
ECM components and soluble ligands (30), and syndecan-4 has
overlapping roles with extracellular TG2 in wound healing and
fibrosis (31, 32). In this study, we show that TG2 has a surpris-
ingly high affinity for heparin and HS, raising the hypothesis
that HSPG are involved in its biological activity. We demon-
strate that HSPGs are essential for the transamidating activity
of TG2 at the cell surface and that syndecan-4 acts as a receptor
for TG2, which is involved in the trafficking and cell-surface
localization, and thus activity of TG2.
EXPERIMENTAL PROCEDURES
Equipment, Reagents, and Antibodies—A 3000 Biacore sys-
tem, CM4 sensor chips, amine coupling kit and HBS-P buffer
were from Biacore AB. Biotin-LC-hydrazide was from Pierce.
Highly purified guinea pig liver TG2 was obtained from
N-Zyme (Darmstadt, Germany) and dissolved in 50 mM Tris-
HCl, pH 7.4, containing 2 mM EDTA. Heparan sulfate from
porcine intestinal mucosa was obtained from Celsus (Cincin-
nati, OH). Heparitinase (from Flavobacterium heparinum) was
obtained from Seikagaku (Tokyo). Surfen (bis-2-methyl-4-ami-
noquinolyl-6-carbamide)was obtained from J.D. Esko (Univer-
sity of California, San Diego). Peptide P3 (purity 95%) was
synthesized by Activotec (Cambridge, UK). Monoclonal anti-
TG2 antibodies TG100, Cub7402 and goat polyclonal anti-TG2
antibody Ab10445/50 were from Abcam; rabbit anti-synde-
can-4 antibody was from Zymed Laboratories Inc./Invitro-
gen. Monoclonal anti-HS antibody 10E4 conjugated with
fluorescein isothiocyanate (FITC) was from Seikagaku
(Tokyo). Monoclonal Na/K-ATPase antibody was from
Abcam (Ab7671). The other reagents, unless stated, were
from Sigma-Aldrich.
Cell Lines andCulture Conditions—Wild type and syndecan-
4/mouse dermal fibroblasts (MDFs) were isolated from skin
biopsies of threemonths old C57BL/6mice and syndecan-4/
mice with C57BL/6 genetic background (33). Cells were main-
tained inDulbecco’smodified Eagle’smediumnutrientmixture
F-12 (DMEM-F12-HAM), supplemented with 10% fetal calf
serum, 2 mM glutamine, non-essential amino acids, and peni-
cillin/streptomycin (100 units/ml and 100g/ml, respectively).
Wild-type and TG2/ mouse embryonic fibroblasts (MEFs)
(34) were donated by G.Melino (Leicester University, UK), and
cultured as described above. Primary human osteoblasts
(HOBs), obtained from femoral heads (35) (a gift from S.
Downes and S. Anderson, University of Nottingham, School of
Biomedical Sciences), and HOB stably transfected with
pSG5-TG and pSVneo (clone TG14) (36) (provided byM. Grif-
fin, Aston University, UK) were maintained in DMEM supple-
mented as above. Swiss-3T3 cell lines capable of inducible
expression of TG2 (clone TG3) (7) (provided by M. Griffin,
Aston University, UK) were induced to express TG2 by 72-h
culture inmediumwithout tetracycline, as previously described
(7, 26).
Cell Transfections—pcDNAhS4was generated by subcloning
full-length human syndecan-4 cDNA, excised from EcoRI/SalI
sites of pBLShS4 (donated by M. Bass, Manchester University)
into EcoRI/XhoI sites of pcDNA3.1(). Transient transfection
of pcDNAhS4 into syndecan-4-null MDF was performed by
electroporation, using NucleofectorII (Amaxa), according to
the manufacturer’s instructions. Transfection efficiency was
60% when estimated by transfecting the reporter plasmid
pEGFPN1 (Clontech).
Reverse Transcription-PCR—RNA was extracted from cells
using RNeasy mini-Kit (Qiagen). Reverse transcription of
DNase-treated RNA (1 g) was performed using Super-
scriptTM-II reverse transcriptase (Invitrogen) and oligo(dT)
(Promega). For PCR, the following primers were used (533):
tggaaagctgtggcgtgat and ccctgttgctgtagccgtat (glyceraldehyde-
3-phosphate dehydrogenase); gggggcattctaagtccagt and tatc-
ccgctatccccctacat (mouse syndecan-4); atgatgttccagattatgct
and gcgtagaactcattggtgggg (human syndecan-4); agtatgagcat-
gggcaacga and atacaggggatcggaaagtg (mouse TG2). The ampli-
fications were conducted at 95 °C (60 s), 60 °C (45 s), and 72 °C
(30 s), for 30 cycles. For syndecan-4, the annealing temperature
was 54 °C.
Analysis of TG2-heparin Interaction by Plate Binding Assay—
Low molecular mass heparin (4–6 kDa) or HS (12 kDa) was
dissolved in PBS and immobilized on 96-well heparin-binding
plates (BD Biosciences) according to the manufacturer’s
instructions. A concentration of 4.6 M was shown to be opti-
mal for assaying heparin-binding proteins using these plates
(37). As positive and negative controls, FN (5 g/ml) and BSA
(5 g/ml) were immobilized on tissue culture plates as
described (13). The plate was washed three times with PBS and
incubated with blocking solution (3% w/v BSA, in PBS, pH 7.4),
for 1 h at 37 °C. After washing three times with PBS, plates were
incubated with gplTG2 (0–212 nM), diluted in blocking buffer
containing 2 mM EDTA, for 2 h at 37 °C. In some instance,
EDTA was replaced by 2 mM CaCl2 or supplemented by inacti-
vating concentrations of GTP-S (100 M). The plate was
washed with PBS, and the bound TG2 was detected by an
enzyme-linked immunosorbent assay-type assay using anti-
TG2 antibody Cub7402 (13). Binding data were fit to “one site
specific binding model” (R2 values of 0.95–0.98) using Graph-
Pad Prism 5.0. The returned Bmax values confirmed that the
interactions between TG2 and heparin/HS were saturable.
Analysis of TG2-heparin Interaction by Surface Plasmon
Resonance—Size-defined heparin (6 kDa), was biotinylated at
its reducing endwith Biotin-LC-hydrazide and immobilized on
a Biacore sensorchip. For this purpose, two flow cells of a CM4
sensorchip were activated with 50 l of 0.2 M N-ethyl-N-(di-
ethylaminopropyl)carbodiimide and 0.05 M N-hydroxysuccin-
imide, before injection of 50 l of streptavidin (0.2 mg/ml in 10
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mM acetate buffer, pH 4.5). The remaining activated groups
were blocked with 50 l of ethanolamine (1 M, pH 8.5). Typi-
cally, this procedure permitted coupling of 3500 resonance
units (RU) of streptavidin. Biotinylated heparin (5 g/ml) in
HBS containing 0.3 M NaCl was then injected across one flow
cell to obtain an immobilization level of 50 RU. The other one
was left untreated and served as a negative control. For binding
assays, 80 l of purified TG2 (0–586 nM), diluted in EDTA-
containing HBS-P buffer (10 mM Hepes, 150 mM NaCl, 2 mM
EDTA, 0.005% (v/v) Surfactant P 20), at 25 °C, were simulta-
neously injected at a flow rate of 10 l/min (kinetic mode)
across the control and heparin surfaces, after which the formed
complexes were washed with running buffer for 5 min. The
sensorchip surface was regenerated with a 1-min pulse of
0.025% SDS followed by a 5-min pulse of 2 M NaCl in HBS-P
buffer. Control sensorgrams were subtracted on line from the
heparin sensorgrams, and results were analyzed using the Biae-
val 3.1 software.
Immunoprecipitations—Confluent cell monolayers were
detached using 2 mM EDTA in PBS, to preserve cell-surface
proteins, and incubated for 1 h at 37 °C in the absence or pres-
ence of heparitinase (30 milliunits/ml) in serum-free medium.
Cells were then homogenized in ice-cold hypotonic Tris-HCl
buffer, pH 7.4, with protease inhibitors and after low speed
centrifugation (to remove remaining whole cells and nuclei),
crude plasma membranes were prepared as previously
described (38). Protein estimation was performed using DC
(Folin) assay (Bio-Rad). Equal amounts of membrane proteins
(500 g) were then solubilized in lysis buffer containing 1% v/v
IGEPAL CA 630, 1% v/v Triton X-100, 0.5% v/v deoxycholic
acid, protease inhibitors and pre-cleared with protein-G-agar-
ose incubation for 1 h at 4 °C.Membrane lysates were subjected
to immunoprecipitation by incubation with rabbit anti-synde-
can-4 antibody (against a syndecan-4-endopeptide) (2 g) or
anti-TG2 antibody TG100 or, as a negative control, rabbit anti-
gliadin antibody (2 g). In some instances the syndecan-4
immunoprecipitates were further incubated with 30 milli-
units/ml heparitinase in lysis buffer at 37 °C for 1 h prior to
further analysis. The immunocomplexes were separated by
reducing SDS-PAGE (10% polyacrylamide) and immuno-
probed with the antibodies against TG2, syndecan-4, or anti-
human plasma FN antibody. Following incubation with the
appropriate horseradish peroxidase-conjugated secondary
antibody, bands were revealed by enhanced EZ-ECL chemilu-
minescence (Geneflow), using Fujifilm image analyzer-3000.
Densitometry of the bands was conducted by Aida ID/evalua-
tion 3.44.
Detection of TG2 inCell Fractions byWesternBlotting—Non-
enzymatically detached cells were fractionated into membrane
and cytosolic fractions as described above. Total and cell frac-
tion lysates (30 g) were resolved by 4–20% gradient SDS-
PAGE (Invitrogen) under reducing conditions, and TG2 was
detected by Western blotting using anti-TG2 polyclonal anti-
body Ab10445/50 (1/1000) in blocking buffer (5% nonfat milk
in TBST). TG2 was revealed by enhanced chemiluminescence,
after incubation with rabbit anti-goat-horseradish peroxidase
(Dako), as described above. Tubulin andNa/K-ATPasewere
revealed as loading controls for cytosolic and membrane frac-
tions, respectively.
Flow Cytometry—For flow cytometry, HOB cell monolayers
were detached with 2 mM EDTA in PBS, pH 7.4. Live, non-
permeabilized cells in suspension (2  106 cells/ml) were
stained for cell-surface HSPGwith anti-HS antibody 10E4 con-
jugatedwith FITC (8g/ml), in serum-freeDMEMmedium for
2 h at 4 °C. After washing in serum-free medium, cells were
fixed in 0.5% (v/v) formaldehyde, and analyzed in a Epics XL-
MCL flow cytometer (Beckman-Coulter). In some instances,
cells in suspension were pre-treated with heparitinase in
serum-freemedium, or kept in serum-freemediumonly, for 1 h
at 37 °C, prior to staining of HS.
Detection of Cell-surface TG2 Activity—TG2 activity associ-
ated with the extracellular surface was assayed in live cells in
culture by measuring the incorporation of biotin-cadaverine
into FN, as described (7, 39). Briefly, cells were plated into
96-well plates (2 104 cells/well) precoated with plasma FN (5
g/ml) in serum-free DMEM (which contains an activating
concentration of Ca2), in the presence of the amine substrate
biotinylated cadaverine (0.1 mM). Cells were allowed to adhere
for 2 h at 37 °C, then washed with PBS, pH 7.4, containing 2mM
EDTA and incubated with 0.1% deoxycholate in PBS, pH 7.4,
containing 2 mM EDTA. The biotylated cadaverine incorpo-
rated into the deoxycholate-insoluble FN matrix was revealed
by incubation with ExtrAvidin peroxidase followed by addition
of 3,3,5,5-tetramethylbenzidine at fixed time and stopped by
0.5 M H2SO4. Spectrophotometric absorbances were measured
at 450 nm.
Detection of TG2 Activity in Cell Fractions—For detection of
TG2 activity in cell homogenates and fractions we used the
method described byBalklava et al. (9). TG2 activity in total and
cell fraction homogenates was quantified by a modification of
the cell-surface TG2 activity protocol, assaying 60g of protein
lysates. Cell lysates were incubated in FN-coated 96-well plates
in the presence of 0.1 mM biotinylated-cadaverine, further sup-
plemented with either 5 mM Ca2 or 2 mM EDTA. The level of
incorporated biotin-cadaverine into FN was revealed as
described above. Background TG2 activity values in the pres-
ence of EDTA were subtracted from activity values at 5 mM
Ca2. A standard curve of TG2 activity was obtained each time
by assaying knownquantities of purifiedTG2, diluted in serum-
free DMEM in the same way.
Fluorescent Staining—For TG2 staining, cells were allowed
to adhere on 8-well chamber slides (104 MDF cells/well), in
normal culture conditions (10% fetal calf serum-containing
medium) for 2 h. Adhered cells were fixed in 3.7% (w/v)
paraformaldehyde in PBS and permeabilized in 0.1% (v/v) Tri-
ton X-100. Fixed and permeabilized cells were blocked in 3%
(w/v) BSA in PBS and then incubated with anti-TG2 antibody
clone Cub7402 (2 g/ml) at4 °C for 15 h, followed by rabbit
anti-mouse IgG-FITC (Dako) diluted 1/100 at 37 °C for 2 h (7,
26). Specificity of Cub7402 was verified in TG2-null cells.
Detection of actin stress fibers and TG2 was achieved by incu-
bation of fixed and permeabilized cells with TRITC-labeled
phalloidin (20g/ml) in blocking buffer, which was added after
incubation with Cub7402, together with the secondary anti-
body after extensive washings in PBS. Detection of syndecan-4
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and TG2 was achieved by incubating the fixed and permeabi-
lized cells with rabbit anti-syndecan-4 antibody (2 g/ml) and
Cub7402, at4 °C for 15 h, followed by either anti-rabbit IgG-
AlexaFluor488 and anti-mouse IgG-Rhodamine RedX (Invitro-
gen) (MDF cells) or donkey anti-rabbit IgG-AlexaFluor568
(Invitrogen) and sheep anti-mouse IgG-FITC (Dako) (diluted
1/100) (HOB cells). There is not overlap in emission spectrum
of the fluorochromes used. To detect matrix-associated TG2,
cells were incubated with the antibody in culture prior to fixa-
tion as described (7, 9). To visualize TG2 activity in situ, cells
were seeded into 8-well glass chamber slides in the presence of
0.5 mM fluorescein-cadaverine (Molecular Probes, Eugene,
OR), for a total of 15 h, as previously described (7, 9). Nuclei
were stained using fluorochrome 4,6-diamidino-2-phenylin-
dole or propidium iodide. Fluorescence images were obtained
by a Leica TCSNTconfocal lasermicroscope and corresponded
to the central optical plane of the basal cell sections.
Cell Attachment—Serum-starved cells (maintained at 0.1%
fetal calf serum for 15 h) were allowed to attach in serum-free
medium to wells (104 cells/well of 96-well plates) either coated
with low molecular mass heparin (2.3–4.6 M) or HS (1.2–4.6
M) and, as positive and negative controls, coated with FN and
BSA (5 g/ml), respectively. The attached cells were fixed and
stained with crystal violet; after extensive washes in PBS adher-
ent cells were solubilized in 30% (v/v) acetic acid, and the
absorbance was measured at 540 nm with a microplate reader
(Bio-Rad) as described (9).
Statistics—All experiments were undertaken at least three
times unless specified. Data are expressed as means S.D. Dif-
ferences between data sets were determined by the Student’s t
test (two-tailed distribution, two-sample equal variance).
RESULTS
Affinity of TG2 for Heparin/HS—To study the interaction of
TG2with heparin, binding assays were developed by using hep-
arin-coated plates where low molecular weight heparin is non-
covalently immobilized to microtiter surfaces in a functionally
active state (37). As previously described for TG2 bound to FN
(13), TG2was allowed to bind immobilized heparin in the pres-
ence of the Ca2 chelator EDTA (2 mM) to prevent TG2 auto-
transamidation. Purified TG2 displayed a concentration-
dependent binding to heparin and the interaction with heparin
was saturable (Fig. 1A). The affinity value of TG2 for heparin
was in the low nanomolar range (Kd 23.20  1.84 nM). TG2
binding to FN-coated wells and lack of binding to BSA were,
respectively, a positive and a negative control for TG2 binding
to heparin (Fig. 1B). The calculated affinity value for FN was
19.47 6.92 nM, a value aligned to that of past reports (40, 41).
Incubation of TG2 with Ca2 (2 mM) resulted in lower binding
to immobilized heparin but the affinity remained high (Kd
40.33  3.75 nM) (Fig. 1A). Incubation of TG2 with GTPS, a
non-hydrolyzable form of GTP that keeps TG2 in the close
GTP-bound form (5), resulted in a comparable affinity binding
(Kd 44.54 10.04 nM) (Fig. 1A). Therefore, the slightly reduced
affinity in the presence of Ca2 is not the result of the Ca2-
boundTG2 conformation. Instead, cations are likely to alter the
conformation and dynamic properties of the heparin polysac-
charide chains (42), thus justifying the slightly altered heparin
recognition in the presence of Ca2. Similar heparin-binding
curves to those obtained in the presence ofCa2were produced
performing the assay in the presence of two other physiologi-
cally relevant cations (K and Mg2) (supplemental Fig. S1).
FIGURE1.TG2binds immobilizedheparinandHS.A, thebindingofpurified
TG2 to low molecular weight heparin was performed over 2 h at 37 °C in the
presence of 2 mM EDTA, 2 mM CaCl2, or 2 mM EDTA plus 100 M GTPS, as
described under “Experimental Procedures.” The mean S.D. of three inde-
pendent experiments performed in triplicate is shown. B, binding assays to
immobilizedFNandBSAwereusedaspositive andnegativebindingcontrols,
respectively. C, binding of purified TG2 to immobilized HS was performed as
described in A, in the presence of 2 mM EDTA. D, affinity of TG2 for heparin
calculated by surface plasmon resonance. TG2 was injected over a heparin
activated surface for 8 min at a flow rate of 10 l/min, after which running
buffer was injected, and the response in RU was recorded as a function of
time. Sensorgrams were obtained with increasing TG2 concentrations, and
analyzed with the Biaeval 3.1 software.
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Heparin is commonly used as a substitute forHS in biochem-
ical investigations (29). To examine whether the interactions
between TG2 and HS were of similar strength as the interac-
tions with heparin, solid binding studies were conducted using
equimolar concentrations of purifiedHS. TheTG2-HS interac-
tion was saturable and was confirmed to be in the low nanomo-
lar range (Kd 15.92  0.96) (Fig. 1C). The interaction did not
depend on the amount of HS as reducing HS to either one-half
or to one-quarter returned a similar range of affinities (supple-
mental Fig. S2).
We further studied the TG2-heparin interaction using sur-
face plasmon resonance, in the same conditions as the solid
phase binding of TG2 to heparin/HS. Here the kinetic of bind-
ing was followed in real-time rather than at equilibrium as in
the solid-binding assay. Heparin was coupled to a Biacore sen-
sorchip, thusmimicking the cell-surface presentation ofHSPG,
and TG2 was perfused above this surface in the presence of 2
mM EDTA. Injection of increasing TG2 concentrations over a
sensorchip activated with 50 RU of heparin gave rise to the
binding curves shown in Fig. 1D. The A B7 AB (Langmuir
1:1) model was first used to fit the data. This returned a “on”
rate constant kon  5.5  103 M1 s1 and a dissociation rate
constant koff 4.95 104 s1, leading to an average dissoci-
ation constant of Kd koff/kon 92.7 4.7 nM. Such a model
returned a 2 value of 4.5, and this was not improved by fitting
the data to other models. This data, taken together with the
solid-binding assays, support the finding of high affinity of TG2
for heparin/HS.
Recognition of Heparin/HS by
Cell-surface TG2—To investigate
whether the TG2-HS affinity value
is physiologically relevant we exam-
ined the recognition of heparin
and HS by cell-surface TG2. We
compared the level of attachment
of wild-type MEFs and TG2-null
MEFs to either heparin-coated or
HS-coated plates, using FN and
BSA coating as a positive and neg-
ative attachment control, respec-
tively. Interference with pro-adhe-
sive serum factors was ruled out by
using serum-starved cells and
omitting serum from the DMEM
culture medium. DMEM con-
tained 1.8 mM Ca2. In these con-
ditions, wild-type and TG2-null
MEFs displayed a similar level of
attachment to FN and very low
attachment to BSA (Fig. 2),
although TG2-null MEF appeared
less spread on FN. Conversely,
wild-type MEFs had a significantly
higher level of attachment to
either heparin or HS, compared
with TG2-null MEFs (Fig. 2). This
finding suggests that cell-surface
TG2 interacts with heparin/HS in
the presence of activating concentrations of Ca2.
Direct Co-association of Cell Membrane TG2 with the HS
Chains of Syndecan-4—The biological significance of the bind-
ing to heparin was then studied by co-immunoprecipitation
analysis of TG2 and the HS cell-surface receptor syndecan-4 in
different cell types. To examinewhether TG2 can act as a ligand
for syndecan-4, membrane preparations of human osteoblasts
(HOB), which are rich in HSPG (43) and express cell-surface
TG2 (36, 44), were subjected to immunoprecipitation analysis.
The expression of syndecan-4 was firstly analyzed by Western
blotting of HOBmembrane lysates using antibody against syn-
decan-4 core protein, which revealed a diffuse polypeptide of
approximate 200 kDa (supplemental Fig. S3, asterisk) and other
diffuse bands of approximate 90, 65, and 40 kDa. The 200-kDa
band was eliminated by enzymatic digestion with heparitinase
(45) and resulted in the clearing of the smear and intensification
of the 40-kDa band (supplemental Fig. S3, arrow), which should
correspond to the syndecan-4 core protein homodimer (46, 47).
For immunoprecipitation, firstly, HOBmembrane lysates were
incubated with either rabbit anti-syndecan-4 antibody or con-
trol rabbit anti-gliadin antibody, and then the immunoprecipi-
tated proteins were analyzed by Western blotting with mouse
anti-TG2 antibody (Fig. 3A). The membrane-located endoge-
nous TG2was specifically co-immunoprecipitated with endog-
enous syndecan-4 in HOB (Fig. 3A, arrowhead). Transfected
human TG2 was also found to be associated with endogenous
syndecan-4 in the stably transfected HOB cell line TG14 (36)
(Fig. 3A, arrowhead). As a control of syndecan-4 immunopre-
FIGURE 2. Adhesion of wild-type (TG2/) and TG2-null (TG2/) MEF to immobilized heparin, HS, and
control BSA. Serum-starved cellswere allowed to adhere for 1 h in serum-freemedium, after that the attached
cells were fixed, stained with crystal violet and quantified as described under “Experimental Procedures.”
Values are the mean  S.D. of a representative experiment performed in triplicate; data were normalized
considering attachment of TG2/onFNas 100. ***, statistically significant differences in adhesion (p	0.001).
The bars represent 20 m.
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cipitation, the membranes were
stripped and re-probed with anti-
syndecan-4 antibody. Syndecan-4
was mainly detected in the high
molecular weight range (200 kDa,
Fig. 3A, asterisk) corresponding to
the glycanated form of syndecan-4.
This result was similar to that of a
previous report (48), and bands
could be distinguished only after a
very short blot development (Fig.
3A). The antibody chains were also
detected, as expected, in the immu-
noprecipitates with rabbit antibod-
ies. Secondly, membrane lysates
were incubated with mouse anti-
TG2 antibody, and the immunopre-
cipitated proteins were analyzed by
Western blotting with rabbit anti-
syndecan-4 antibody (Fig. 3B). Syn-
decan-4 co-precipitated with mem-
brane TG2 in both transfected and
untransfected HOB (Fig. 3B, aster-
isk). Identification of the 200-kDa
polypeptide and lower molecular-
size bands as syndecan-4 was shown
by treatment of the immunoprecipi-
tates with heparitinase, which elim-
inated these bands and revealed the
core protein dimer of approximate
40 kDa (Fig. 3B, arrow). As a control
of TG2 precipitation, the stripped
membranes were reprobed with
anti-TG2 antibody showing a pro-
tein of the expected size (75 kDa)
(Fig. 3B, arrowhead). TG2 associa-
tionwith syndecan-4was verified by
dual immunofluorescent staining of
TG2 and syndecan-4 in HOBs,
which were found to co-localize at
the cell border and in cells’ tail (Fig.
3C, arrows).
To investigate whether TG2
bound to the HS chains of synde-
can-4, cells suspensions were incu-
batedwith heparitinase, which leads
to specific degradation of cell-sur-
face HS, prior to immunoprecipita-
tion of syndecan-4. Flow cytometry
analysis of HS after heparitinase
treatment demonstrated cleavage
of HS chains in about half the HS
fromHOB cells in suspension (Fig.
3D). Removal of cell-surface HS
chains proportionally decreased
the level of TG2 associated with
syndecan-4 immunoprecipitates
(Fig. 3E, arrowheads), suggesting
FIGURE 3. Association of TG2 to syndecan-4. A, membrane lysates fromwild-type and TG2-transfected HOB
(HOB-TG14) were immunoprecipitated with anti-syndecan-4 antibody (S4) and, as negative controls, anti-
gliadin antibody (Gl) or protein G-Agarose only (B). Immunoprecipitates were subjected to Western blot anal-
ysis for TG2 and syndecan-4. Arrowhead indicates TG2; asterisk, glycanated S4 (200 kDa); Hc antibody heavy
chain (50 kDa).B, the samemembrane lysateswere immunoprecipitatedwith anti-TG2 antibody, digestedor
not with heparitinase (Hep) and subjected to Western blot analysis for syndecan-4 and TG2. Arrow, S4 core
protein dimer. C, TG2 and syndecan-4 co-localization in HOB. TG2 was detected by mouse anti TG2 antibody
and syndecan-4 with rabbit anti syndecan-4 antibody followed by sheep anti-mouse IgG FITC and donkey
anti-rabbit IgG AlexaFluor568. Two separate fields are shown. Co-localization is pointed by the arrows. The bar
indicates 20 m. D, flow cytometry of live HOB stained with a FITC-conjugated monoclonal anti-HS chains
antibody, before and after heparitinase (Hep) digestion of HS. The arrow indicates the shift of mean fluores-
cence. E, the syndecan-4 immunoprecipitations described in A were repeated using membrane preparations
from cells preincubated or not with heparitinase (Hep) prior to immunoprecipitation. TG2 indicates 200 ng of
standard purified TG2. Three replicate blots are shown, and quantification of syndecan-4 co-immunoprecipi-
tated TG2 is presented in the histogram. Arrowheads point to TG2 co-immunoprecipitated with syndecan-4.
Values represent mean intensity relative to that of TG2 standard S.D. *, p	 0.05; **, p	 0.01. F, the synde-
can-4 immunoprecipitations described in Awere conducted in the presence of peptide P3 that mimics the FN
binding site within TG2. Arrowheads indicate TG2 or FN co-immunoprecipitatedwith syndecan-4.G, inhibition
of TG2-FN binding, assayed using 20 nM and 50 nM purified TG2 on FN in the presence of increasing concen-
trations of peptide P3. The experiments were repeated at least three times.
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that the majority of TG2 binding is mediated by the HS
chains of syndecan-4.
To investigate whether syndecan-4 was co-associated with
cell-surface TG2 also in fibroblasts, we utilized a Swiss 3T3 cell
line with tetracycline-regulated inducible expression of TG2
(7). We found that membrane-located endogenous TG2 co-
immunoprecipitated with syndecan-4 (supplemental Fig. S4A),
and this co-association was confirmed in membrane prepara-
tions of cells induced to overexpress TG2 by tetracycline with-
drawal (supplemental Fig. S4A). Similarly to HOB cells,
removal of HS from Swiss 3T3 fibroblasts decreased the level of
TG2 associated with syndecan-4 immunoprecipitates (supple-
mental Fig. S4B).
Because the Hep II domain of FN associates with the HS
chains of syndecan-4, and FN is also a high affinity binding
partner of TG2, it could reasonably mediate the TG2-synde-
can-4 interaction. To examine this possibility we interfered
with TG2-FN binding using competitive concentrations of a
synthetic peptide that mimics the FN binding site within TG2
(P3) (40). HOB cells were plated on a FN matrix preincubated
with peptide P3 (100 M) prior to cell seeding. After 1 h, both
adherent and non-adherent cells were collected, and mem-
brane preparations subjected to immunoprecipitation with
anti-syndecan-4 antibody (Fig. 3F) followed by Western blot-
ting with anti-TG2 or anti-FN antibody. Displacement of TG2
fromFNdid not lead to a decrease in the level of TG2 associated
with syndecan-4 (densitometric values with and without 100
M P3 were 1.2  0.18 and 1.0  0.07, respectively, p  0.32)
(Fig. 3F). Western blot analysis of FN in syndecan-4 immuno-
precipitates also revealed no changes in FN (densitometric val-
ues with andwithout P3were 1.0 0.14 and 1.0 0.11, respec-
tively, p  0.86) (Fig. 3F). Control plate assays of TG2-FN
binding, confirmed that incubation of two different concentra-
tions of purified TG2 with increasing concentrations of P3
(0–150M) led to a significant inhibition of TG2 binding to FN
(Fig. 3G). In conclusion, our findings suggest the direct associ-
ation of TG2 with the HS chains of syndecan-4.
HS Chains Influence TG2 Activity at the Cell Surface—To
examine whether the association of TG2 with HS chains, par-
ticularly those of syndecan-4, influences TG2 cell-surface
cross-linking activity, primary MDFs were chosen as a model,
becauseMDFs with targeted deletion of syndecan-4 were avail-
able to us. Moreover, the components of the dermal matrix,
such as type I/III collagen, fibrillin-1, and FN are all major sub-
strates of TG2 transamidation (11, 12, 49, 50). TG2 extracellu-
lar activity was measured in live cells in culture by using a pre-
viously described plate assay (7, 39). In a first set of experiments,
wild-typeMDF (MDF S4/) were treated to reduce their level
of cell-surface HS by either incubation with heparitinase or
surfen (12 M), a general antagonist of HS (51). A significantly
lower level of TG2 transamidation was found at the surface of
wild-type MDF pre-treated with both heparitinase and surfen
compared with untreated cells (Fig. 4A). Titration of the cell-
surface TG2 inhibition effect by surfen revealed an IC50 of 6.8
M (supplemental Fig. S5). Any possible interference of surfen
with the cell-surface TG2 activity assay itself (incorporation of
biotin cadaverine into FN) was ruled out by producing statisti-
cally similar dose-response curves of TG2 activity when using
purified TG2 in the absence and in the presence of 6 and 12M
surfen (supplemental Fig. S6). When the role played by synde-
can-4 was investigated, a significantly lower level of TG2 activ-
ity was measured at the surface of syndecan-4-null MDF (MDF
S4/) compared with wild-typeMDF (Fig. 4A). The total level
of TG2 expression was found to be statistically similar in wild-
type and syndecan-4-null MDF when assayed by reverse tran-
scription-PCR of total RNA, or total TG2 activity assay, or
Western blotting of the whole cell lysates (Fig. 4B). This finding
indicates that the loss in cell-surface TG2 activity in syndecan-
4-null MDF is not due to a change in total TG2. The residual
level of extracellular TG2 was significantly higher in syndecan-
4-null MDF than in surfen or heparitinase-treated wild-type
MDF (Fig. 4A), and both surfen and heparitinase treatments
significantly lowered cell-surface TG2 in syndecan-4-null cells
(Fig. 4A), suggesting that syndecan-4 is not the only HSPG
implicated with extracellular TG2 activity. To test TG2 activity
in syndecan-4-null MDF with added-back syndecan-4, we
cloned syndecan-4 cDNA in the mammalian expression vector
pcDNA3.1 and confirmed its expression in syndecan-4-null
MDF transfected with this construct (Fig. 4C). Reconstitution
of syndecan-4 in syndecan4-null MDF restored cell-surface
TG2 activity to wild-type levels (Fig. 4A). Conversely, hepariti-
nase or surfen treatment of the syndecan-4-null MDF with
reconstituted syndecan-4 further inhibited extracellular TG2
activity (Fig. 4A), thus confirming the role of the syndecan-4HS
chains. Therefore, the present findings demonstrate that syn-
decan-4 significantly affects the extracellular activity of TG2,
but other HSPG are also involved.
The plate assay of TG2 activity in live cells in culture was
developed to detect the whole extracellular TG2 activity, either
located at the cell surface or bound to FN in 2 h cell adhesion to
FN (7, 39). To rule out the possibility that the deficiency in
extracellular TG2 found in cells either lacking functional HS or
syndecan-4 could be due to improper engagement of cells with
FN, we quantified the attachment of surfen-treated wild-type
and syndecan-4-null MDF in serum-free conditions. As shown
in Fig. 4D, neither syndecan-4 deletion nor surfen treatment
significantly altered MDF attachment to FN in 2 h. Treatment
with heparitinase was also shown not to diminish cell attach-
ment to FN (13), thus confirming that the deficiency in TG2 is
not due to an alteration of cell-substratum interaction.
To visualize extracellular TG2 activity, cells were seeded and
grown for 15 h in medium containing a cell-permeable fluores-
cent amine TG substrate (fluorescein-cadaverine) as previously
described (7, 9). Fluorescein-cadaverine was found to be pre-
dominantly cross-linked in cell-matrix glutaminyl substrates
and in the pericellular matrix of wild-typeMDF (Fig. 5). Synde-
can-4-null cells displayed a significantly lower level of in situ
TG2 activity compared with wild-type cells (Fig. 5), in agree-
ment with measurements of cell-surface TG2 by plate assay
(Fig. 4A). To verify that TG2 activity was responsible for the
fluorescent signal, a specific site-directed inhibitor of TG,
R-283, which targets the Ca2-activated form (9), was utilized
in negative control experiments, showing a drastic inhibition of
the in situ TG reaction in both wild-type and syndecan-4 null
MDF (Fig. 5). The specificity of the in situ reaction for TG2was
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confirmed by the absence of fluores-
cence in TG2/ MEFs compared
with wild-typeMEFs (supplemental
Fig. S7A).
Defects of TG2 Export in Synde-
can-4-null MDF—After showing
that theHS chains are critical for the
biological activity of TG2 at the cell
surface, and that TG2 directly binds
to the HS chains of syndecan-4, we
investigated whether HS binding
had a direct influence on the enzy-
matic activity of TG2 or, alterna-
tively, on the cell trafficking/local-
ization of TG2. To address the first
hypothesis we assayed the Ca2-de-
pendent transamidation of purified
TG2 in the presence and absence of
heparin. As shown in Fig. 6, heparin
did not significantly alter the cross-
linking activity of a range of TG2
concentrations (2–8 nM), chosen to
be similar to the level of TG2 we
estimated to be present at the sur-
face of MDF (data not shown).
We then tested whether the
removal of HSPG, and in particular
syndecan-4,may interfere with TG2
exposure at the cell surface. In a first
set of experiments we undertook
immunofluorescent staining of TG2
in fixed and permeabilized MDF
with or without syndecan-4. TG2
was found to be predominantly
located at the cell periphery of wild-
typeMDF, concentrated at the basal
surface (Fig. 7A, arrows). Instead,
staining of syndecan-4-null MDF
revealed amarked reduction in TG2
at cell/matrix contacts, which was
accompanied by an increase in the
cytosolic staining (Fig. 7A). Using
double fluorescence labeling, we
verified that anti-TG2 antibody
labeled large peripheral cell-matrix
adhesions, which appeared to be
connected to the end of actin fila-
ments, as shown by the merged
images (Fig. 7B, arrowheads). In
addition, the anti-TG2 antibody
decorated extracellular structures
(Fig. 7B, small arrows), consistent
with TG2 secretion. The localiza-
tion of TG2 at focal adhesions and
in the pericellular matrix was previ-
ously described (8, 26); however, the
concentration of TG2 at the cell
periphery is more dramatic in pri-
FIGURE 4. Cell-surface HS affect extracellular TG2 activity of primary dermal fibroblasts adherent to FN.
A, cell-surface TG2 activity was measured in wild-type (S4/), syndecan-4-null (S4/), and syndecan-4-null MDF
with added-back S4by cell transfectionof pcDNAhS4. In some instances, cellswere either pretreatedwith hepariti-
nase (Hep) orwith theHS antagonist surfen (12M) or incubatedwithmediumonly, for 1 h at 37 °C. Afterward cells
were seeded on FN and assayed for TG2 activity in the presence of Hep or surfen. The cell-surface TG2 activity was
expressed as normalized mean absorbance at 450 nm S.D., using wild-type untreated samples as normalizers
(typical opticaldensity0.6). **, statistically significantdecrease incell-surfaceTG2activity (p	0.01).B, theexpres-
sion of TG2 inwild-type and syndecan-4-null MDFwas analyzed by reverse transcription-PCR, using triplicate sam-
plesof total RNA/cell type, followedbyquantificationofbands intensitiesbydensitometry. Values (TG2expression)
aremean ratios of TG2 intensity versus control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The expres-
sion of total TG2 in cell homogenates was evaluated by means of a TG2 activity plate assay (Total TG2 activity), as
described under “Experimental Procedures.” TG2 activity data represent mean values  S.D. of three separate
experiments, using values of wild-type cells (typical optical density 0.5) as normalizers. TG2 expression was also
analyzed byWestern blotting of total cell homogenates using polyclonal anti-TG2 antibody Ab10445/50. C, re-ex-
pression of syndecan-4 (hS4) in syndecan-null MDF was tested by reverse transcription-PCR on RNA isolated 48 h
after transfectionofpcDNAhS4or theemptyvectorpcDNA. Endogenousmouse syndecan-4 (mS4)wasdetected in
wild-type MDF (S4/). Expression of glyceraldehyde-3-phosphate dehydrogenase was monitored to confirm
equal loading of RNA. MW, molecular DNA markers (1-kb Promega). D, S4/ and S4-null MDF were allowed to
attach to FN-coated wells, in the same conditions as in the cell-surface TG2 assay described in A (in serum-free
conditions), but in the absence of amine substrate. Where indicated, cells had been incubated with 6 and 12 M
Surfen. At the end of the 2-h incubation, cell attachment was quantified as described under “Experimental Proce-
dures.” The bars indicate 20m.
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mary fibroblasts, as shown here, compared with immortalized
fibroblasts where cytosolic TG2 is predominant (7, 8, 26). We
next studied whether syndecan-4 co-localized with TG2 in
MDF. Double immunolabeling showed that antibodies against
TG2 and syndecan-4 co-localized at large cell-matrix adhesion
structures (Fig. 7C, arrows). To specifically detect secreted,
matrix-bound TG2, cells were incubated with anti-TG2 anti-
body before cell fixation, as described (7, 9, 26), which revealed
a much lower level of extracellular TG2 in syndecan-4-null
MDFcomparedwithwild-typeMDF (Fig. 7D and supplemental
Fig. S8). These findings were consistent with the lower level of
cell-surface TG2 activity measured in syndecan-4-null MDF
compared with wild-type MDF (Fig. 4A).
Because TG2 was not found on the surface and matrix of
syndecan-4-nullMDF to the same extent as wild-typeMDF, we
analyzed whether it was retained intracellularly. Wild-type and
syndecan-4-nullMDFwere detachedwith non-enzymatic solu-
tion, to preserve cell-surface components, solubilized, and frac-
tionated into cytosol andmembrane fractions; equal weights of
proteins were then fractionated and loaded onto a SDS-polyac-
rylamide gel in the same amount.We found that themembrane
fractions of syndecan-4-null MDF contained a significantly
lower amount of TG2 antigen and activity then the membrane
fractions of wild-type MDF (Fig. 7, E and F). Conversely, the
cytosolic fractions of syndecan-4-null MDF had a significantly
higher amount of TG2 antigen and activity compared with the
cytosolic fractions of wild-type MDF (Fig. 7, E and F). Equal
loading was verified by stripping and reprobing the cytosolic
fractions with anti-tubulin antibody and the membrane frac-
tions with anti-Na/K ATPase antibody. The combined level of
TG2 activity was not significantly different in wild-type and
syndecan-4-null MDF (Fig. 7F), in agreement with measure-
ments of TG2 in total cell lysate shown in Fig. 4B. The specific-
ity of the enzyme activity assay for TG2 was confirmed by the
absence of cross-linking activity in TG2/ MEFs compared
with wild-type MEFs (supplemental Fig. 7B). These data sug-
gest that syndecan-4 contributes to increase the concentration
of TG2 in the membrane and at the cell surface.
DISCUSSION
The data shown in this study assign to HSPG the function of
regulating the cell-surface biological activity and trafficking of
TG2. Firstly, we have investigated the binding affinity of TG2
for the HS analogue heparin using solid binding assays and sur-
face plasmon resonance. Kinetic studies demonstrated high
affinity of TG2 for heparin, giving dissociation constant values
in the nanomolar range. These findings were validated using
TG2 binding assays toHS, which aremore representative of the
GAG chains of cell-surface HSPG, showing that the interaction
between TG2 and HS or heparin are of similar strength. In our
solid binding experiments, the apparent Kd for the interaction
ofTG2 for immobilized heparan sulfatewas16nM.TheKd for
FN, a well established TG2 binding partner (40, 41) was 19
nM, a value that compareswell with those calculated in previous
solid-phase binding studies (8–10 nM) (41). Therefore, our
data show for the first time that the affinity of TG2 for HS is
strong, and it is comparable to that for FN. As a result, these
findings suggest the formation of a possible ternary complex of
TG2, FN, and HS, where the affinity of TG2 for HS is compa-
rable to the affinity of TG2 for FN.
Secondly, to support the physiological relevance of the high
affinity binding of TG2 to HS, we have shown that cell-surface-
associated TG2 is crucial for the cell recognition of immobi-
lized heparin and HS. In the same experiments, cell surface-
associated TG2 did not similarly affect recognition of FN
(judged by measuring cell attachment), although it did influ-
FIGURE 5. Visualization of in situ TG2 activity in wild-type and syndecan-
4-null dermal fibroblasts. In situ TG2 activity of S4/ and S4-null MDF was
visualized by the incorporation of fluorescein-cadaverine into endogenous
substrates. R-283, a site-specific inhibitor of TG activity was used as a control
at 200 M. Nuclei were stained with propidium iodide to facilitate cell count-
ing. The average fluorescence produced by fluorescein excitation was quan-
tifiedby Leica TCSNT imageprocessing in five random fields andexpressed as
mean fluorescence/cell. *, significantly different TG2 activity (p 	 0.05). The
bars correspond to 40 m.
FIGURE 6. Heparin binding does not affect the cross-linking activity of
purified TG2. The cross-linking activity of purified TG2 was assayed in the
absence and presence of heparin as described under “Experimental Proce-
dures.”Data are themeanvaluesS.D. of a representativeexperimentunder-
taken in triplicate. p 0.05.
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ence cell spreading. This is not surprising, because it has been
shown that expression of antisense RNA for TG2 does not
affect cell attachment to FN but results in changes in cell
spreading (52). However, the contribution of cell-surface TG2
becomes crucial when the main RGD-dependent adhesion
pathway is blocked (13). After showing that cell-surface TG2
interacts with immobilizedHS, we have also demonstrated that
endogenous TG2 physically co-precipitates with syndecan-4 in
cell membranes of different cell types, and that this association
is significantly reduced by cleavage of cell-surface HS chains.
Because obstruction of the FN recognition site within the
N-terminal -sandwich domain of TG2 (40) did not alter TG2-
syndecan-4 co-precipitation, this finding suggests that TG2
directly interacts with the HS chains of syndecan-4. The TG2-
syndecan-4 association has been verified by TG2 and synde-
can-4 labeling showing that TG2 and syndecan-4 are co-local-
ized at large, peripheral cell-matrix adhesions that determine
cell shape (46, 53). Thus the presence of syndecan-4 at focal
adhesions (46, 47) may facilitate the recruitment of cell-surface
TG2.
Thirdly, to test the hypothesis thatHSPGs are involved in the
biological enzymatic activity of TG2 we have investigated the
role of HS binding on the extracellular cross-linking activity of
TG2 in live cells in culture, by using a well established assay (7,
9, 39, 44). This assay specificallymeasures TG2, as the activity is
inhibited by preincubation of cells with anti-TG2 antibody (7,
39), and it is completely abolished by deletion of TG2 in TG2-
null MEF. In this study, specific interference with the function
of cell-surface HS chains was carried out by both enzymatic
digestion and antagonism using surfen, a compound that binds
low molecular weight heparin and neutralizes HS-associated
cellular responses (51). Recently, surfen was shown to block
HS-regulated FGF2 binding and signaling in Chinese hamster
ovary cells (51). Neutralization of cell-surface HS chains
resulted in a dramatic alteration of extracellular TG2 activity in
wild-type fibroblasts. We showed that the HS chains of synde-
can-4 controlled a significant portion of the extracellular TG2
activity, because extracellular TG2 transamidation was mark-
edly decreased in syndecan-4-null MDF and was rescued by
re-expression of syndecan-4, if the functional role of HS chains
was not impaired. Visualization of TG2 activity “in situ” in pri-
mary fibroblasts, confirmed that absence of syndecan-4 leads to
inhibition of TG2 activity, which was predominant at the cell
surface of primary dermal fibroblasts. This finding is consistent
with evidence of TG2 externalization and tight control of intra-
cellular TG2 activity by tri- and di-phosphate nucleosides and
low Ca2 (3, 7, 54). Therefore, syndecan-4 binding plays a
major contribution in determining extracellular TG2 activity;
however, because alteration ofHS chains leads to amore radical
effect on TG2 activity we speculate that the binding of TG2 is
not exclusive to the HS chains of syndecan-4, and the type of
HSPG involved may indeed be cell-specific.
Syndecan-4 has been recently implicated in integrin co-sig-
naling induced by adhesion to an experimental matrix of puri-
fied exogenous TG2. In this wounding model of matrix frag-
mentation, purified guinea pig liver TG2 plays a structural,
non-catalytic role (14, 31). We have now identified syndecan-4
as an important binding partner for endogenous, cell-secreted
TG2 and shown that this binding has a wider physiological sig-
nificance on the biological activity of TG2. Therefore, synde-
can-4 may act as an overall partner of extracellular TG2, being
involved in the structural adhesive and, as reported here, the
Ca2-dependent cross-linking activity of TG2.
The present data conclusively point to a direct role of the HS
portion of HSPG in the extracellular activity of TG2 in primary
fibroblasts. We therefore asked whether this function could be
due to the direct influence of HSPG binding on TG2 enzymatic
activity or on the cell-surface availability of TG2. We showed
that the transamidation activity of TG2 was not affected by
heparin binding per se, while absence of syndecan-4 led to a
marked decrease in TG2 at peripheral adhesions and in the
pericellularmatrix, with proportional TG2 accumulation in the
cytosol. Therefore, our data have revealed that heparin binding
influences extracellular TG2 transamidation indirectly, by
affecting the targeting of TG2 to the cell surface. The possibility
that absence of HS may affect the stability of externalized TG2
was ruled out by finding a consistently similar level of total TG2
in wild-type and syndecan-4 null cells. Previous work with a
truncated form of TG2 disabled for FN binding and fused to
-galactosidase, showed a lower level of -galactosidase activ-
ity in COS-7 cells transfected with the truncated form, com-
pared with the full-length form of TG2, suggesting that FN
binding is also important for the extracellular localization
and/or stability of TG2 (26). The limit of that work was in the
possible folding alteration of themutant TG2. For some uncon-
ventionally secreted proteins (like FGF-2) translocation must
occur in a folded state, and subsequent work has shown the
importance of TG2 conformation for secretion (9). In this
study, we conducted the opposite experiment to look at
whether cells lacking TG2-binding partners had less cell-sur-
FIGURE 7. Importance of syndecan-4 in cell-surface TG2 location. A, S4/ and S4-null MDF were fixed, permeabilized, and stained with monoclonal
anti-TG2 antibody (Cub7402), which was revealed by using a FITC-conjugated secondary antibody. Nuclei were stained with 4,6-diamidino-2-phenylindole.
Specimens were imaged using fluorescence or both phase contrast and fluorescence illumination in combination. The arrows indicate TG2 localization at the
cell periphery. The bars correspond to 20 m. B, TG2 staining was performed as described in A; actin stress fibers were stained using TRITC-phalloidin.
Arrowheads indicate TG2 localization at cell-matrix adhesions; small arrows indicate TG2 released in the ECM. The bars correspond to 20 m. C, TG2 and
syndecan-4 were co-immunodetected using Cub7402 and anti-polyclonal anti-syndecan-4 antibody, which were revealed by anti-mouse IgG-Rhodamine
RedX and anti-rabbit IgG-Alexafluor488, respectively. Nuclei were stained with 4,6-diamidino-2-phenylindole. The arrows point at the cell-matrix adhesion
sites where TG2 and syndecan-4 co-localize. The bars indicate 20 m. D, for detection of matrix-associated TG2, S4/ and S4-null MDF were cultured in the
presence of Cub7402 before fixation and incubation with FITC-conjugated secondary antibody. Average signal of matrix TG2 per single cell was quantified in
three separate fields and is displayed in the graph. Values are normalized considering S4/ signal as 100. ** indicates p 	 0.01. E, analysis of the cellular
distribution of TG2 in S4/ and S4-null MDF. Cells were fractionated into membrane (M) and cytosolic (C) fractions, as described under “Experimental
Procedures.” The level of TG2 was then assessed by Western blotting using anti-TG2 antibody and equal loading was verified on a parallel blot of membrane
and cytosolic fractions, respectively, immunoprobedwith anti-Na/KATPase antibody (membranemarker) and anti-tubulin antibody. F, S4/ and S4-nullMDF
were fractionated and the total TG2 activity assayed as described under “Experimental Procedures.” The asterisks indicate a significant difference between
S4/ and S4-null MDF membrane and cytosolic TG2 (p	 0.02). There was no significant difference in the total level of TG2 between the two cell types.
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face TG2 and demonstrated that in the absence of syndecan-4,
TG2 externalization is reduced. The association of TG2 with
FN at the cell surface and in the pericellular matrix was previ-
ously reported (7, 26). We have now shown that TG2 also co-
localizes with syndecan-4, which in turn also co-associates with
early assembled FN (55). Therefore, future investigations are
warranted to test whether once syndecan-4 recruits TG2 at the
cell surface, it contributes to direct the association of TG2 with
FN leading to TG2 deposition into the ECM.
Recent evidence have ascribed a role to HSPG in both mem-
brane secretion and endocytosis (56), raising the possibility that
HSPG could influence both the secretion and internalization of
TG2. This last possibility is intriguing as Zemskov et al. (10)
have demonstrated that internalization of TG2 requires the
endocytic receptor LRP1, and this receptor has been shown to
act in concert withHSPG (57). Althoughwe cannot rule out the
possibility of a dual function of HSPG in TG2 externalization
and internalization, with our syndecan-4 knockout and HS
function-blocking cell models we show that lack of syndecan-
4/HS leads to a lower level of cell-surface TG2 and a parallel
accumulation of cytosolic TG2. Therefore, our findings sup-
port a role forHSPG in the trafficking of TG2 to the cell surface.
There are several classified unconventional mechanisms of
secretion, involving either import into endosomal subcompart-
ments (e.g. IL1), direct translocation across the plasma mem-
brane (e.g. Leishmania protein HASPB), exosomes/membrane
blebbing (e.g. galectins), or direct translocation across the
plasma membrane (e.g. FGF1/2) (58). Recently, cell-surface
counter receptors have emerged as essential components of
non-conventional secretion for galectin1 and FGF-2 (58, 59). In
FGF-2 secretion, cell-surface HS function as an extracellular
“molecular trap” driving themembrane transport of fully folded
FGF-2 by passive diffusion (60, 61).
Given the length and flexibility of the HS chains, our data
suggest that HSPGs, like syndecan-4, act as cell-surface recep-
tors to direct the secretion of TG2 from the plasma membrane
to the cell surface, where TG2 is catalytically active and leads to
matrix stabilization events, which are essential for tissue func-
tion and repair.
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